Core tests face new rivals as margin pressure grows
- Third quarter 2026 testing revenue reached $146.4 million, a 15 percent increase from the prior year.
- Management lowered incremental volume expectations for Decipher Prostate due to new competition from digital pathology tools.
- The company is expanding its urology sales force by 30 percent to defend market share, which will reduce near-term profitability.
- Afirma thyroid tests continued to outperform with 19 percent revenue growth in the third quarter.
- The recent Convergent Genomics acquisition adds urine-based testing to the bladder cancer portfolio.
A defensive transition
Veracyte is moving from a period of unhindered growth into a more defensive stance. While third quarter 2026 testing revenue grew a solid 15 percent to $146.4 million, the flagship Decipher Prostate test missed volume expectations. The core issue is competitive distraction. Novel digital pathology and artificial intelligence tools are capturing physician attention, forcing sales teams to spend more time explaining differences rather than closing new orders.
To defend its market share and stabilize adoption, Veracyte is increasing its urology sales force by 30 percent. This heavy investment will pressure near-term margins and pull expected early 2027 profitability below previous targets. The key question for investors is whether a larger team can successfully reaccelerate Decipher growth without diluting focus on newer products.
The bull case still rests on a highly profitable testing engine and a newly completed bladder cancer portfolio. Afirma thyroid testing continues to deliver exceptional growth, and the recent acquisition of Convergent Genomics adds the UroAmp platform. This gives Veracyte a comprehensive bladder cancer offering spanning tissue, blood, and urine tests.
Execution risk has increased. The company must prove it can absorb the costs of a larger sales team, fend off digital pathology alternatives, and simultaneously launch its major pipeline products like TrueMRD.
Evidence turns into paid tests
Veracyte makes money when doctors order its cancer tests and payers, such as Medicare or private insurers, agree to pay for them. Most revenue comes from U.S. laboratory developed tests, which are diagnostic tests designed and run inside a certified lab.
The business works best when clinical data proves that a test changes patient care. Solid evidence and guideline inclusion help doctors trust the test, raising overall volume. Better payer contracts and clear billing then raise the cash collected per test.
This model requires constant education and defense. When new technologies like digital pathology enter the market, sales teams must spend time contextualizing molecular testing instead of core selling. This slows down the pace of new adoption.
Because testing is nearly all of total revenue, reimbursement is the central pillar. The company relies on its specialized sales channels to defend existing tests and launch new ones simultaneously.
Core tests fund new bets
Decipher Prostate
The historical main growth driver, currently facing adoption headwinds from digital pathology alternatives.
Afirma
A thyroid nodule test that continues to be a steady pillar for the company with durable volume growth.
TrueMRD
Launched for muscle-invasive bladder cancer, TrueMRD looks for small signs that cancer may be returning.
UroAmp
A proprietary urinary tumor DNA platform added via the 2026 Convergent Genomics acquisition to expand bladder cancer testing.
Prosigna LDT
A breast cancer test that represents a major growth option, depending on clinical evidence and share gains.
Decipher Bladder
An earlier bladder cancer test that helps Veracyte build deeper ties with urologists.
Almost entirely a testing business
The mix uses third quarter 2026 revenue. Testing makes up nearly 97 percent of total sales, placing heavy reliance on the Decipher and Afirma franchises.
What could break the story
Digital pathology distraction
High impact · High oddsNew digital pathology and artificial intelligence tools are drawing physician attention away from core molecular tests. The sales team must spend more time contextualizing these tools, which slows core product adoption.
Margin pressure from sales expansion
Medium impact · High oddsVeracyte is expanding its urology sales force by 30 percent to defend market share. This heavy investment will pull near-term profitability below previous targets.
Reimbursement pressure
High impact · Medium oddsVeracyte recognizes testing revenue based on what it expects to collect. A negative coverage change from Medicare or lower payment rates could hurt revenue and margin immediately.
LDT regulation adds cost and delay
Medium impact · Medium oddsThe FDA rule issued in 2024 phases out broad enforcement discretion for many laboratory developed tests. Newer tests could face more stringent review, raising costs and stretching future launch timelines.
In one breath
What does Veracyte actually sell?
Veracyte sells genomic cancer tests. These tests read patterns in tumor or tissue samples to help doctors decide whether a patient needs more treatment or can avoid it.
Why is Decipher important to Veracyte?
Decipher Prostate is the company's main growth engine. However, its recent growth has slowed as doctors explore new digital pathology alternatives.
Why does reimbursement matter so much?
Most Veracyte revenue comes from tests that need payment from Medicare or insurers. If payers cut rates or deny more claims, profit falls even when doctors order tests.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 8, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Diagnostics & Research companies
Companies near Veracyte, Inc. in Finn's Diagnostics & Research industry ranking.

